Antibe Therapeutics Inc. (TSE:ATE – Get Rating) Senior Officer Scott Wilson Curtis acquired 20,000 shares of the firm's stock in a transaction dated Friday, July 8th. The stock was purchased at an average cost of C$0.62 per share, with a total value of C$12,400.00. Following the completion of the acquisition, the insider now directly owns 80,000 shares of the company's stock, valued at approximately C$49,600.

ATE stock opened at C$0.62 on Wednesday. The company has a market capitalization of C$31.86 million and a P/E ratio of -1.16. Antibe Therapeutics Inc. has a twelve month low of C$0.59 and a twelve month high of C$3.65. The business has a 50 day simple moving average of C$0.66 and a 200-day simple moving average of C$0.70. The company has a current ratio of 13.07, a quick ratio of 11.92 and a debt-to-equity ratio of 0.29.

About Antibe Therapeutics (Get Rating)

Read More

• Should These Two Airlines Be In Your Portfolio?
• Old Dominion Freight Line (ODFL): This Dividend Growth Stock Deserves Your Attention
• Is There a Reasonable Price to Buy Stitch Fix Stock?
• 3 Smid Caps Under $20 Set to Recover
• Continuining to Assess Tesla's Future As The EV Market Becomes Increasingly Competitive

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.